- Home
- LPRO vs ABEO Comparison
LPRO vs ABEO Comparison
Compare LPRO & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- ABEO
- Stock Information
- Founded
- LPRO 2000
- ABEO 1974
- Country
- LPRO United States
- ABEO United States
- Employees
- LPRO N/A
- ABEO N/A
- Industry
- LPRO Finance: Consumer Services
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- LPRO Finance
- ABEO Health Care
- Exchange
- LPRO Nasdaq
- ABEO Nasdaq
- Market Cap
- LPRO 232.4M
- ABEO 256.9M
- IPO Year
- LPRO N/A
- ABEO 1980
- Fundamental
- Price
- LPRO $2.45
- ABEO $5.69
- Analyst Decision
- LPRO Buy
- ABEO Strong Buy
- Analyst Count
- LPRO 6
- ABEO 6
- Target Price
- LPRO $3.44
- ABEO $18.00
- AVG Volume (30 Days)
- LPRO 1.3M
- ABEO 1.1M
- Earning Date
- LPRO 08-07-2025
- ABEO 08-11-2025
- Dividend Yield
- LPRO N/A
- ABEO N/A
- EPS Growth
- LPRO N/A
- ABEO N/A
- EPS
- LPRO N/A
- ABEO N/A
- Revenue
- LPRO $17,672,000.00
- ABEO N/A
- Revenue This Year
- LPRO $314.67
- ABEO N/A
- Revenue Next Year
- LPRO $15.32
- ABEO $323.51
- P/E Ratio
- LPRO N/A
- ABEO N/A
- Revenue Growth
- LPRO N/A
- ABEO N/A
- 52 Week Low
- LPRO $0.70
- ABEO $3.93
- 52 Week High
- LPRO $6.92
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- LPRO 65.26
- ABEO 47.54
- Support Level
- LPRO $2.20
- ABEO $5.68
- Resistance Level
- LPRO $2.56
- ABEO $5.93
- Average True Range (ATR)
- LPRO 0.16
- ABEO 0.26
- MACD
- LPRO 0.04
- ABEO -0.01
- Stochastic Oscillator
- LPRO 84.67
- ABEO 56.25
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.